Why the study?
Despite advances in oral anticoagulation for stroke prevention, a significant residual vascular risk associated with silent AF, bleeding, premature sudden death, and heart failure remains.
This review highlights the residual vascular risk in AF patients despite NOAC therapy and calls for optimized management strategies in Portugal.
No takes yet. Share an insight, caveat, or question.
Residual vascular risk persists in AF despite NOACs; leaves open optimized strategies in Portugal pending prospective data.
Ferreira et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: